List view / Grid view

Articles

test

15 June 2023 | By

sadfasdf

Targeting SARS-CoV-2 replication with inhibitors of lipid metabolism

30 September 2021 | By

One approach towards efficient drug targeting efforts for COVID-19 is to repurpose medicines developed for other diseases. Here, Professor Christopher Basler outlines a recent study, published in Cell Reports, where scientists from the Institute for Biomedical Sciences at Georgia State University, US, in collaboration with industry partners, developed assays to…

High-throughput 3D cell migration assays in organ-on-a-chip technologies

30 September 2021 | By , , ,

Organ-on-a-chip models can provide an alternative to cell cultures, animal models and traditional assays. In this article, Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek explore the advantages of organ-on-a-chip technologies and how they can enable the in vitro study of three-dimensional (3D) cell migration in…

CRISPR-Cas9-based gene dropout screens: a powerful platform for drug discovery

23 September 2021 | By

CRISPR holds great promise in advancing pharmacological research and has fuelled the rapid expansion of using gene-edited cells for drug discovery processes. CRISPR-Cas9 dropout screens have emerged as a useful tool for high-throughput large-scale loss-of-function screens, which seek to identify the relationship between genotype and phenotype. Dr Pushpanathan Muthuirulan, Research…

The diversity of synthetic biology applications

23 September 2021 | By

Synthetic biology processes can be useful to therapeutic development, diagnostics and vaccine advancement. Drug Target Review’s Victoria Rees spoke with Dr Jim Collins, Termeer Professor of Medical Engineering & Science at MIT and Founding Core Faculty & Lead, Living Cellular Devices at the Wyss Institute at Harvard University, to explore…

An IgM antibody platform to tackle SARS-CoV-2 and its variants

23 September 2021 | By

Despite the rapid deployment of vaccines among global populations, therapeutics such as antibodies are still required. Here, Dr Steve Carroll, Vice President of Pre-clinical Sciences at IGM Biosciences, explains how a potential Immunoglobulin M (IgM) antibody treatment has been developed that shows promise for combatting SARS-CoV-2 and variants of concern in pre‑clinical…